Understanding the Setup: (ENTA) and Scalable Risk
This article provides an in-depth analysis of Enanta Pharmaceuticals Inc. (ENTA), highlighting a weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including long, momentum breakout, and short positions, along with AI-generated signals and risk management parameters. The analysis focuses on resistance and support levels, offering specific entry, target, and stop-loss prices for different trading approaches.
Enanta Pharmaceuticals (ENTA) Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus
Enanta Pharmaceuticals (ENTA) reported a Q1 2026 revenue of US$18.6 million and an EPS loss of US$0.42, with a net income loss of US$11.9 million, indicating continued unprofitability despite narrowing losses on a trailing 12-month basis. Analysts emphasize revenue growth as the main upside, but persistent losses and a lower-than-average price-to-sales ratio, coupled with shareholder dilution and insider selling, raise concerns about the company's path to profitability.
The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Enanta Pharmaceuticals (NASDAQ:ENTA) exceeded analyst expectations in its first-quarter results, with revenues of US$19m surpassing forecasts by 22% and statutory losses significantly smaller than predicted. Despite these strong results, analysts have not significantly changed their revenue estimates for 2026, though loss per share forecasts have seen a promising decrease. The consensus price target remains at US$19.25, indicating that the improved loss estimates have not yet translated into a long-term positive impact on stock valuation, and the company still faces a forecast revenue decline worse than the industry average.
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results
Enanta Pharmaceuticals (NASDAQ: ENTA) exceeded revenue expectations in its first quarter, reporting US$19 million, and significantly reduced its statutory loss per share to US$0.42. Analysts have updated their estimates, maintaining a revenue forecast of US$65.3 million for 2026, but notably decreasing the projected loss per share to US$2.35, indicating improved sentiment. Despite the positive adjustments, the company is still expected to experience revenue decline, performing worse than the wider biotech industry.
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT
HC Wainwright & Co. has reiterated a Buy rating on Enanta Pharma (ENTA) with a price target of $20, maintaining a steady outlook. This decision comes despite varied analyst actions in recent months, highlighting consistent confidence in the biotechnology company's future performance. Analysts' average target price for ENTA is $19.13, suggesting a potential upside of 37.99% from its current price.
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for
Enanta Pharmaceuticals will present preclinical data for EDP-978, their KIT inhibitor for mast cell-mediated, Type 2 immune diseases, at the 2026 AAAAI Annual Meeting. The presentations will cover the discovery of the potent and selective inhibitor and its pharmacokinetic profile with potential for once-daily dosing. These findings will be shared in two poster sessions on February 27, 2026.
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT | ENTA Stock News
HC Wainwright & Co. has reiterated a Buy rating for Enanta Pharma (ENTA), maintaining a price target of $20, signaling stable confidence in the company's future. This rating aligns with the average target price of $19.13 from 8 analysts, suggesting a 37.99% upside from the current price. Enanta Pharma is a biotechnology company focused on developing small-molecule candidates for virology and immunology applications.
HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)
HC Wainwright has reaffirmed its "Buy" rating for Enanta Pharmaceuticals (NASDAQ:ENTA), setting a price target of $20.00, which suggests a 44.6% upside. This comes after the biotechnology company reported better-than-expected earnings and revenue for the quarter. The consensus among analysts is a "Moderate Buy" with an average price target of $20.33.
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals will present preclinical data for its KIT inhibitor, EDP-978, at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data will be showcased in two poster presentations focusing on EDP-978's discovery as a potent and selective KIT inhibitor for mast cell-mediated diseases, and its favorable pharmacokinetic profile suggesting once-daily dosing potential. EDP-978 is in development for the treatment of Type 2 immune diseases.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals reported financial results for its fiscal first quarter ended December 31, 2025, showing total revenue of $18.6 million and a net loss of $11.9 million. The company is advancing its RSV treatment pipeline, including zelicapavir, and expanding its immunology programs with new candidates targeting MRGPRX2, KIT, and STAT6 inhibitors. Enanta maintains a strong financial position with $241.9 million, projecting a cash runway into fiscal 2029.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) reported a Q1 loss of $0.42 per share, exceeding the Zacks Consensus Estimate of a $0.54 loss and showing improvement from a $1.05 loss a year ago. The biotechnology company also surpassed revenue estimates, posting $18.62 million against an expected $15.58 million. Despite these positive earnings surprises, Enanta Pharmaceuticals' shares have declined by 14.3% year-to-date, underperforming the S&P 500.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals, a clinical-stage biotechnology company, announced its financial results for the fiscal first quarter ended December 31, 2025, reporting a total revenue of $18.6 million primarily from MAVYRET/MAVIRET royalties. The company highlighted significant progress in its RSV treatment portfolio, with zelicapavir advancing towards a Phase 3 study, and expanded its immunology pipeline with a new program targeting MRGPRX2 inhibitors. Despite a net loss of $11.9 million, Enanta anticipates its current cash and future royalty revenue will fund operations and development programs into fiscal year 2029.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202
Enanta Pharmaceuticals reported its financial results for the fiscal first quarter ended December 31, 2025, showing total revenue of $18.6 million and a net loss of $11.9 million. The company highlighted significant progress in its RSV treatment portfolio, including preparing zelicapavir for Phase 3 studies, and expanded its immunology pipeline with new programs targeting MRGPRX2, KIT, and STAT6 inhibitors. Enanta maintains a strong financial position of $241.9 million, anticipating a cash runway into fiscal 2029.
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA) reported earnings results, beating analyst estimates with an EPS of -$0.42 against a consensus of -$0.54 and revenue of $18.62M exceeding expectations. Despite a 2.4% stock increase to $13.83, the company remains unprofitable with negative ROE and net margin, and analysts hold a "Moderate Buy" rating with an average target price of $20.33. Insider selling of over 11,000 shares was noted, while institutional investors hold approximately 95% of the stock.
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings
Enanta Pharmaceuticals Inc. reported a net loss of $11.9 million, or 42 cents per share, for its fiscal first quarter. The biotechnology firm's revenue for the quarter reached $18.6 million. This financial report was produced by Automated Insights using data from Zacks Investment Research.
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings
Enanta Pharmaceuticals Inc. reported a net loss of $11.9 million, or 42 cents per share, for its fiscal first quarter. The biotechnology firm recorded $18.6 million in revenue during this period. The article was produced by Automated Insights using data from Zacks Investment Research.
The Technical Signals Behind (ENTA) That Institutions Follow
This article analyzes Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) using AI models to identify institutional trading signals. It highlights strong near-term sentiment, potential support and resistance levels, and an exceptional risk-reward setup targeting an 18.8% gain. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are presented for varying risk profiles.
Earnings Preview For Enanta Pharma
Enanta Pharma (NASDAQ: ENTA) is set to release its quarterly earnings on February 9, 2026, with analysts expecting an EPS of $-0.74. The company's stock has seen a 174.08% increase over the last 52 weeks, and analysts have a "Buy" consensus rating with an average one-year price target of $18.5. Despite strong revenue growth, Enanta Pharma faces challenges with its net margin, return on equity, and debt-to-equity ratio compared to peers.
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday
Enanta Pharmaceuticals (ENTA) is slated to announce its Q1 2026 earnings on Monday, February 9th, with analysts forecasting a loss of ($0.54) per share and revenue of $16.14 million. The company's stock currently trades around $12.90, and despite a "Moderate Buy" consensus rating from analysts with an average price target of $20.33, insiders have recently sold shares. Institutional ownership remains very high at approximately 95%.
Precision Trading with Enanta Pharmaceuticals Inc. (ENTA) Risk Zones
This article analyzes Enanta Pharmaceuticals Inc. (ENTA) focusing on risk zones and trading strategies. It highlights a potential negative sentiment in the mid-term despite long-term strength, identifying a significant risk-reward short setup. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for near, mid, and long-term perspectives.
Enanta (NASDAQ: ENTA) seeks 1.6M-share boost to 2019 equity plan
Enanta Pharmaceuticals is asking stockholders to approve an amendment to its 2019 Equity Incentive Plan to add 1,600,000 shares, representing 5.5% of common shares outstanding, at its virtual annual meeting on March 11, 2026. The company states that this increase is crucial for attracting and retaining talent through equity awards, which are a central component of its compensation program. Stockholders will also vote on the election of two Class I directors, executive compensation on an advisory basis, and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a consensus "Moderate Buy" rating from seven research firms, with an average 12-month price target of $20.33, significantly higher than its recent open of $12.61. Despite reporting mixed quarterly results with continued unprofitability, analysts expect an EPS of -$4.65 for the current year. Insider selling by CEO Jay Luly and other executives, totaling $170,149 in the last 90 days, contrasts with substantial institutional ownership of nearly 95%.
Technical Reactions to ENTA Trends in Macro Strategies
This article provides a technical analysis of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA), indicating divergent sentiment across various time horizons and suggesting choppy market conditions. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis, generated by AI models, details near-term, mid-term, and long-term signal strengths, support, and resistance levels for the stock.
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Buy" Rating from HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Enanta Pharmaceuticals (NASDAQ:ENTA) with a target price of $20.00, implying a 48.81% upside. Despite the company reporting negative margins and forecasted negative EPS for the current year, analysts collectively give the stock a "Moderate Buy" rating with an average target of $20.33. Insider selling totaling over $170,000 occurred in the last 90 days, while institutional investors and hedge funds reportedly own nearly 95% of the stock.
Baird reiterates Outperform rating on Enanta Pharmaceuticals stock By Investing.com
Baird has reaffirmed its Outperform rating and set a $20.00 price target for Enanta Pharmaceuticals (NASDAQ:ENTA), indicating a potential 49% upside. This follows Enanta's announcement of its 2026 milestones, including new immunology and inflammation programs and upcoming IND filings. The company also anticipates aligning with the FDA on a Phase 3 program for its RSV drug, zelicapavir, and recently reported a narrower-than-expected Q4 loss.
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Enanta Pharmaceuticals announced updates on its research and development programs and key milestones for 2026, focusing on its RSV and immunology portfolios. The company is advancing zelicapavir to Phase 3 for RSV, expanding its immunology pipeline with a new MRGPRX2 inhibition program, and progressing clinical candidates EDP-978 and EPS-3903. Enanta also highlighted its strong financial position with a cash runway extending into fiscal 2029 and will present its 2026 outlook at the J.P. Morgan Healthcare Conference.
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Enanta Pharmaceuticals provided an update on its research and development programs and outlined key milestones for 2026. The company is advancing its RSV portfolio, including discussions with the FDA for a Phase 3 study of zelicapavir, and expanding its immunology pipeline with new programs targeting MRGPRX2, KIT, and STAT6 inhibitors. Enanta maintains a strong financial position, expecting cash runway into fiscal 2029, and will present further details at the 44th Annual J.P. Morgan Healthcare Conference.
ENTA - Enanta Pharmaceuticals Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Enanta Pharmaceuticals (ENTA), a clinical-stage biotechnology company focused on small molecule drug discovery for viral infections and liver diseases. The news covers clinical trial results, FDA regulatory updates, partnership announcements, financial reports, and capital market activities, all of which influence the company's stock value and strategic direction. Investors can track developments related to drug candidates for RSV and hepatitis C, intellectual property, and financial performance.
Trading the Move, Not the Narrative: (ENTA) Edition
This article presents an AI-generated analysis for Enanta Pharmaceuticals Inc. (NASDAQ: ENTA), highlighting a weak near-term sentiment but strong mid and long-term outlook. It details specific trading strategies, including long, breakout, and short positions, along with support and resistance levels across different time horizons. The analysis emphasizes an exceptional risk-reward setup targeting a 20.2% gain against 0.3% risk.
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. announced that its President and CEO, Jay R. Luly, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:00 p.m. PT. A live webcast and replay of the event will be available on the company's website. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases, with current programs in RSV and a hepatitis C treatment (glecaprevir) sold by AbbVie.
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that its President and CEO, Jay R. Luly, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be webcast live and a replay will be available afterward. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. announced that its President and CEO, Jay R. Luly, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. A live webcast of the presentation will be available on the company's website. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Enanta Pharmaceuticals Insider Ups Holding During Year
Enanta Pharmaceuticals saw net insider buying over the last year, with President Jay Luly making a significant purchase. However, the last three months have shown insider selling, suggesting some insiders may not view the stock as cheap. Despite recent selling, insiders still own 4.4% of the company, indicating a reasonable degree of alignment with shareholders.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Analysts
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from analysts, with six "buy" and one "sell" rating, and an average 12-month price target of $20.33. The article highlights recent insider stock sales by CEO Jay R. Luly and Tara Lynn Kieffer, totaling approximately $170,149, reducing insider ownership to 13.89%. Despite negative margins, the company recently beat EPS estimates, reporting -$0.87 against a -$1.13 consensus, and institutions own about 94.99% of the stock.
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) saw a 5.9% stock rally due to significant trading volume and growing investor optimism for its lead candidate, zelicapavir. The biotechnology company anticipates a smaller quarterly loss and increased revenues, and a positive trend in earnings estimate revisions suggests potential for further stock appreciation. The stock currently holds a Zacks Rank #3 (Hold).
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Enanta Pharmaceuticals (NASDAQ:ENTA) shares have seen a 27% gain in the last thirty days, contributing to a 145% increase over the past year. Despite this strong price performance, the company's price-to-sales (P/S) ratio of 6.8x is significantly lower than the industry average, suggesting it may still be undervalued. However, the low P/S ratio is likely due to a disappointing 3.4% revenue decline last year and a projected annual growth of only 1.5% for the next three years, contrasting sharply with the industry's predicted 130% annual growth.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Enanta Pharmaceuticals (NASDAQ:ENTA) shares recently gained 27% in 30 days, contributing to a 145% increase over the last year. Despite this strong performance, its Price-to-Sales (P/S) ratio of 6.8x is significantly lower than the industry average, suggesting it may still be undervalued. This low P/S ratio is attributed to the company's declining revenue and a projected future growth of only 1.5% per annum, compared to the industry's 130% forecast.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares have recently surged by 27% in the last month, contributing to a 145% increase over the past year. Despite this strong price performance, the company's price-to-sales (P/S) ratio of 6.8x is significantly lower than the industry average, suggesting it may still be undervalued. This low P/S ratio is largely attributed to the company's declining revenue and modest future growth forecasts compared to its industry peers.
Enanta Pharmaceuticals falls on public offering of common stock
This article reports that Enanta Pharmaceuticals' stock fell following the announcement of a public offering of its common stock. It details the size and pricing of the offering, as well as the expected gross proceeds and the intended use of these funds.
Have Insiders Sold Enanta Pharmaceuticals Shares Recently?
Enanta Pharmaceuticals President Jay Luly recently sold US$67k worth of stock, reducing his holding by 0.6%, though he had previously bought shares at a lower price earlier in the year. The article notes that while insider selling occurred, insiders still own about 4.5% of the company, indicating some alignment with shareholders. This suggests that recent selling is not a major concern given prior transactions and existing insider ownership.
Enanta Pharma CSO Or Yat Sun sells $34k in stock By Investing.com
Or Yat Sun, CSO of Enanta Pharmaceuticals (NASDAQ: ENTA), sold 2,390 shares worth approximately $34,009 to cover withholding taxes. Following the sale, Sun directly owns 371,392 shares. Enanta Pharmaceuticals recently reported a narrower-than-expected Q4 loss and increased revenue driven by royalties from AbbVie’s MAVYRET/MAVIRET.
Have Insiders Sold Enanta Pharmaceuticals Shares Recently?
Enanta Pharmaceuticals President Jay Luly recently sold US$67k worth of stock, reducing his holding by a small 0.6%. This follows an earlier purchase of shares at a significantly lower price earlier in the year. While there has been recent selling, insiders still own a notable 4.5% of the company, suggesting alignment with shareholder interests.
Have Insiders Sold Enanta Pharmaceuticals Shares Recently?
Enanta Pharmaceuticals President Jay Luly recently sold US$67k worth of stock, reducing his holding by 0.6%. This follows an earlier purchase of US$256k in shares when the price was significantly lower. While there was recent selling, the article notes that insiders still own a fair amount of the company's shares.
Enanta Pharma CSO Or Yat Sun sells $34k in stock
Or Yat Sun, the Chief Scientific Officer of Enanta Pharmaceuticals (NASDAQ:ENTA), sold 2,390 shares of company stock for approximately $34,009 to cover withholding taxes. Following the transaction, Or Yat Sun directly owns 371,392 shares. The company recently reported a narrower-than-expected Q4 loss, benefiting from decreased research and legal expenses.
Enanta Pharma CBO Luu sells $19,836 in stock
Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, sold 1,394 shares of common stock for approximately $19,836 to cover withholding taxes. This sale followed the company reporting a narrower-than-expected loss in Q4 and increased revenue driven by royalties from AbbVie's hepatitis C virus regimen. The company also benefited from reduced research and legal expenses.
Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025.
This article announces that certain options of Enanta Pharmaceuticals, Inc. are subject to a lock-up agreement that ends on November 30, 2025. The lock-up period for these options is 61 days, starting from September 30, 2025. This agreement restricts directors and executive officers from selling or transferring their common stock or related securities without consent.
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
Enanta Pharmaceuticals (NASDAQ:ENTA) currently holds US$143.2m in debt but offsets this with US$188.9m in cash, resulting in a net cash position of US$45.7m. While the company has notable liabilities, its cash reserves are sufficient to manage its debt safely. Despite recent revenue shrinkage and a net loss, the company's net cash position indicates it can sustain operations at its current burn rate for over two years.
Enanta Pharma posts narrower-than-feared Q4 loss as expenses decline
Enanta Pharmaceuticals (NASDAQ:ENTA) reported a narrower-than-expected fourth-quarter loss due to reduced research and legal expenses, with shares closing 6% higher. The company posted a Q4 loss of $0.87 per share, beating analyst expectations, despite revenue slightly missing estimates at $15.13 million. Enanta also highlighted pipeline advancements and strengthened financial position, projecting current resources to fund operations into fiscal 2029.
Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade
Wall Street analysts project Enanta Pharmaceuticals (ENTA) could see a 44.9% upside, with a mean price target of $17.57, following a 13.7% gain in the past four weeks. While individual price targets can be misleading, the company's strong Zacks Rank #2 (Buy) and positive earnings estimate revisions suggest potential for near-term growth. Investors are cautioned to treat price targets with skepticism but consider the agreement among analysts and revised EPS estimates as indicators of potential upside.
Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development (ENTA)
Enanta Pharmaceuticals (ENTA) maintains a "Buy" rating due to the promising secondary endpoints of zelicapavir in RSV despite missing its primary endpoint. The company's pipeline is further strengthened by positive data from EDP-323 and robust preclinical immunology programs. A recent equity raise has extended its cash position into fiscal 2029, supporting continued development, with IND filings for KIT Inhibitor EDP-978 and STAT6 inhibitor EPS-3093 expected in 2026.
